Research Analysts Offer Predictions for DWTX Q3 Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Research analysts at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for shares of Dogwood Therapeutics in a note issued to investors on Friday, August 14th. HC Wainwright analyst S. Lee now forecasts that the company will post earnings per share of ($0.15) for the quarter, down from their prior forecast of ($0.14). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($0.55) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.80) EPS, Q1 2027 earnings at ($0.16) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.17) EPS, Q4 2027 earnings at ($0.17) EPS, FY2027 earnings at ($0.66) EPS and FY2028 earnings at ($0.60) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Friday, July 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $12.00.

Dogwood Therapeutics Price Performance

NASDAQ DWTX opened at $2.06 on Tuesday. The company has a market capitalization of $69.28 million, a price-to-earnings ratio of -0.23 and a beta of 1.71. Dogwood Therapeutics has a 12 month low of $1.28 and a 12 month high of $9.50. The company’s fifty day moving average price is $1.58 and its two-hundred day moving average price is $2.03.

Dogwood Therapeutics (NASDAQ:DWTX) last released its earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.20).

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics as of its most recent filing with the SEC. 9.05% of the stock is owned by hedge funds and other institutional investors.

Key Dogwood Therapeutics News

Here are the key news stories impacting Dogwood Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $12 price target, implying substantial potential upside from Dogwood Therapeutics’ roughly $2 share price. The firm’s upcoming virtual key opinion leader event could also increase investor attention around Halneuron® and its potential use in chemotherapy-induced neuropathic pain. Dogwood to Host Virtual KOL Event
• Neutral Sentiment: Dogwood will host the virtual KOL event on September 1, featuring pain and neuropathy specialists who will discuss the unmet need and treatment landscape for chemotherapy-induced neuropathic pain. The event is a potential catalyst, but it does not provide new clinical or regulatory data yet.
• Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to $(0.80) from $(0.56), FY2027 to $(0.66) from $(0.60), and FY2028 to $(0.60) from $(0.54). It also reduced quarterly forecasts, including Q3 2026 to $(0.15) from $(0.14) and Q1–Q4 2027 estimates to losses of approximately $(0.16)–$(0.17) per share.
• Negative Sentiment: The sharpest revision was for Q4 2026, which moved from an expected $0.14 profit to a $(0.16) loss. The estimate reductions reinforce concerns about Dogwood’s cash needs and path to profitability, particularly because the company recently reported a quarterly loss of $(0.34) per share, below the $(0.14) consensus estimate.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.